Merck moved ahead in the race for an oral PCSK9 by securing the first U.S. approval for enlicitide, beating AstraZeneca’s timeline expectations. Analysts framed the result as a milestone for Merck and highlighted the relevance of the FDA voucher pathway to faster review for qualified innovations.